News in brief

Chromadex reports 97% increase in ingredient sales

Chromadex reports 97% increase in ingredient sales

The success and demand for Chromadex’s Niagen-branded nicotinamide riboside ingredient are driving ingredient sales for the Californian company, with more research to be published expected to further boost the ingredient.

The company’s recent financial results showed a 97% in ingredient sales, which Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented was largely a result of the first order the company received from 5LINX for Niagen and its PurEnergy pterostilbene-caffeine ingredient.

“Based on visibility of sales activity from both our existing customers and our business development pipeline, we anticipate steady growth in our ingredient segment to continue for the foreseeable future,” he said.

Nicotinamide riboside (NR) is found naturally in trace amounts in milk and other foods, and is a more potent, no-flush version of Niacin (vitamin B3). Published research has shown that NR is a potent precursor to NAD+ in the mitochondria of animals. NAD+ is an important cellular co-factor for improvement of mitochondrial performance and energy metabolism.

Chromadex is currently available in High Performance Nutrition’s (HPN) N(R) product to support neuroprotection in contact sports, and the company also has a three-year marketing deal with Thorne Research to take Niagen into a series of first-to-market products for the healthcare-practitioner channel. Most significantly, in a deal worth a potential $62 million over four years, Chromadex granted 5LINX the marketing rights for Niagen for use in dietary supplements exclusively in the network marketing sales channel in the United States, Canada and Philippines.

“Media outlets are starting to highlight peer reviewed research studies from esteemed institutions on the potential health benefits of NAD+ precursors, such as NR,” said Jaksch. “We expect new research will continue to be published which will further validate the health benefits of NR. We plan to add to that research by beginning our first clinical study on Niagen in the second quarter.”

For the first quarter of 2014, the company reported an increase in net sales of 32% to reach just over $3 million, largely due to the massive increase in ingredient sales. 

Related News

ChromaDex signs marketing deal with consulting firm

ChromaDex signs marketing deal with consulting firm

Cyanotech hires exec for newly created COO position

Cyanotech hires exec for newly created COO position

$5 million in additional funding will help ChromaDex bridge through to profitability, CEO says

$5 million in additional funding will help ChromaDex bridge through to profitability, CEO says

ChromaDex succeeds in boosting ingredient sales by 182%  in face of continuing losses

ChromaDex succeeds in boosting ingredient sales by 182% in face of continuing losses

HPN's N(R) product to support neuroprotection in contact sports - the only commercial product currently available, but more are coming, says Frank Jaksch.

Chromadex CEO: ‘We think Niagen has a much bigger market, like omega-3’

Nicotinamide riboside is found milk and other sources.  ChromaDex's version is a synthesized, bioidentical form.

ChromaDex signs $62 million deal for Niagen, Purenergy ingredients

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'